AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%
Last update at 2024-05-16T16:25:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -22.72700M | -8.47700M | -4.72300M | -6.23000M | 9.64M |
| Minority interest | - | - | - | - | - |
| Net income | -37.66900M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Selling general administrative | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M |
| Selling and marketing expenses | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M |
| Gross profit | 5.48M | 5.17M | 1.33M | 0.12M | 24.78M |
| Reconciled depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Ebit | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 8.92M |
| Ebitda | -7.64700M | -8.52600M | -7.90900M | -9.22900M | 8.98M |
| Depreciation and amortization | 7.61M | 0.14M | -1.84500M | 0.32M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 9.84M |
| Other operating expenses | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M |
| Interest expense | 0.00300M | 0.02M | 3.42M | 0.59M | 0.28M |
| Tax provision | 0.00000M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Interest income | - | - | - | 4.61M | 0.28M |
| Net interest income | -0.00300M | -0.02100M | -0.73600M | -0.59300M | 0.28M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 14.94M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Total revenue | 5.64M | 5.26M | 3.65M | 0.53M | 26.88M |
| Total operating expenses | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M |
| Cost of revenue | 0.16M | 0.09M | 2.32M | 0.41M | 2.10M |
| Total other income expense net | -7.47400M | 0.19M | 1.34M | 3.31M | -0.48100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Net income applicable to common shares | - | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 56.03M | 80.10M | 37.28M | 19.98M | 25.01M |
| Intangible assets | - | 0.62M | 0.06M | 0.04M | 0.06M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.49M | 1.77M | 0.87M | 1.21M | 1.21M |
| Total liab | 20.25M | 27.12M | 24.07M | 22.44M | 23.10M |
| Total stockholder equity | 35.78M | 52.99M | 13.21M | -2.46300M | 1.91M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.94M | 1.89M | 1.50M | 2.93M | 0.74M |
| Common stock | 293.41M | 293.41M | 235.01M | 224.53M | 222.34M |
| Capital stock | 293.41M | 293.41M | 235.01M | 224.53M | 222.34M |
| Retained earnings | -352.08400M | -334.61900M | -322.65900M | -316.89100M | -309.78100M |
| Other liab | - | 19.32M | 19.00M | 16.53M | 17.51M |
| Good will | 0.00000M | 8.13M | 8.81M | 8.05M | 8.21M |
| Other assets | - | 0.34M | 0.34M | 0.36M | 0.42M |
| Cash | 50.61M | 65.30M | 24.27M | 7.84M | 14.51M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 7.04M | 7.77M | 5.01M | 5.66M | 5.60M |
| Current deferred revenue | 2.95M | 4.82M | 2.19M | 0.99M | 0.07M |
| Net debt | -50.43200M | -65.13900M | -24.08700M | -6.93500M | -14.51200M |
| Short term debt | 0.11M | 0.13M | 0.14M | 0.65M | 3.50M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.18M | 0.16M | 0.18M | 0.90M | - |
| Other stockholder equity | 95.42M | 94.87M | 101.91M | 89.81M | 1.91M |
| Property plant equipment | - | 0.19M | 0.18M | 0.62M | 0.07M |
| Total current assets | 55.49M | 70.82M | 27.89M | 10.91M | 16.26M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 44.23M | 4.34M | -10.55300M | -6.36500M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.16M | 3.67M | 1.68M | 0.66M | 0.29M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.23M | 0.07M | 0.02M | 1.20M | 0.24M |
| Accounts payable | 2.04M | 0.93M | 1.19M | 1.09M | 1.28M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.96700M | -0.67800M | -1.04500M | 0.09M | 0.01M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 235.01M | 224.53M | 222.34M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.32M | 0.34M | 0.34M | 0.36M | 0.42M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.54M | 9.28M | 9.39M | 9.07M | 8.76M |
| Capital lease obligations | 0.18M | 0.16M | 0.18M | 0.90M | - |
| Long term debt total | - | - | - | 0.26M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01200M | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Change to liabilities | - | 3.64M | 3.08M | 0.13M | -0.18600M |
| Total cashflows from investing activities | - | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Net borrowings | - | -0.12700M | -0.26500M | -0.61400M | -0.61400M |
| Total cash from financing activities | -0.11800M | 51.04M | 20.47M | 3.89M | 3.89M |
| Change to operating activities | - | -1.09900M | -1.23400M | -1.04200M | -1.85300M |
| Net income | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Change in cash | -14.68900M | 41.03M | 16.43M | -6.67400M | 6.73M |
| Begin period cash flow | 65.30M | 24.27M | 7.84M | 14.51M | 7.78M |
| End period cash flow | 50.61M | 65.30M | 24.27M | 7.84M | 14.51M |
| Total cash from operating activities | -13.68000M | -8.58100M | -4.12900M | -10.72500M | 6.83M |
| Issuance of capital stock | 0.00000M | 34.20M | 23.50M | 4.99M | 0.00000M |
| Depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Other cashflows from investing activities | - | -0.02000M | 0.05M | 0.05M | -0.05000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.16100M | -0.05600M | 1.18M | -0.97100M | 0.31M |
| Change to account receivables | - | -0.73900M | -1.33000M | -0.72900M | 2.17M |
| Sale purchase of stock | - | - | - | 5.30M | - |
| Other cashflows from financing activities | 0.02M | 16.96M | -2.76700M | -0.48100M | -0.03500M |
| Change to netincome | - | -2.85800M | -2.37700M | -3.10400M | 2.73M |
| Capital expenditures | 0.01M | 0.64M | 0.03M | 0.03M | 0.00900M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.60M | 2.50M | 2.40M | -2.44400M | -0.15100M |
| Stock based compensation | 0.54M | 0.31M | 0.06M | 0.79M | 0.57M |
| Other non cash items | 7.76M | -1.56800M | 1.88M | 0.28M | -1.31800M |
| Free cash flow | -13.69100M | -9.22000M | -4.12900M | -10.72500M | 6.82M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AEZS Aeterna Zentaris Inc |
-0.2149 2.49% | 8.43 | - | - | 1.42 | 0.37 | 0.16 | 1.26 |
| NVO Novo Nordisk A/S |
-1.63 1.21% | 133.03 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.57 0.43% | 132.69 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.20 0.27% | 438.69 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
1.03 1.09% | 96.00 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
315 Sigma Drive, Summerville, SC, United States, 29486
| Name | Title | Year Born |
|---|---|---|
| Dr. Klaus Paulini Ph.D. | Pres, CEO & Exec. Director | NA |
| Dr. Nicola Ammer M.D. | Chief Medical Officer & Sr. VP of Clinical Devel. | NA |
| Dr. Matthias Gerlach | Sr. VP Manufacturing & Supply Chain | NA |
| Mr. Giuliano La Fratta | Sr. VP of Fin. & CFO | NA |
| Dr. Michael Teifel | Sr. VP of Non-Clinical Devel. & Chief Scientific Officer | NA |
| Dr. Eckhard G. Guenther Ph.D. | Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany | NA |
| Ms. Amélie Métivier | Assistant Sec. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...